Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
- Market Cap ₹ 5,724 Cr.
- Current Price ₹ 1,316
- High / Low ₹ 1,584 / 970
- Stock P/E 67.9
- Book Value ₹ 383
- Dividend Yield 0.00 %
- ROCE 3.99 %
- ROE 4.97 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 3.44 times its book value
- Earnings include an other income of Rs.131 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Retail Industry: Trading
Part of Nifty Total Market BSE SmallCap BSE Allcap Nifty Microcap 250 BSE Consumer Discretionary
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|
105 | 137 | 178 | 318 | 443 | |
137 | 191 | 222 | 353 | 471 | |
Operating Profit | -32 | -54 | -44 | -34 | -28 |
OPM % | -30% | -39% | -25% | -11% | -6% |
23 | 27 | 53 | 90 | 131 | |
Interest | 2 | 5 | 11 | 22 | 7 |
Depreciation | 7 | 9 | 10 | 9 | 8 |
Profit before tax | -18 | -41 | -12 | 24 | 88 |
Tax % | 0% | 0% | 0% | -58% | |
-18 | -41 | -12 | 38 | 84 | |
EPS in Rs | -1,811.38 | -106.10 | -30.31 | 8.84 | 19.37 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 45% |
TTM: | 69% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 60% |
TTM: | 4556% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|
Equity Capital | 0.10 | 4 | 4 | 43 | 43 |
Reserves | -31 | -72 | -84 | 1,583 | 1,620 |
540 | 674 | 775 | 18 | 16 | |
23 | 47 | 68 | 125 | 105 | |
Total Liabilities | 533 | 654 | 764 | 1,769 | 1,785 |
50 | 51 | 41 | 34 | 31 | |
CWIP | 2 | 0 | 0 | 0 | 0 |
Investments | 39 | 39 | 41 | 41 | 228 |
442 | 563 | 682 | 1,694 | 1,525 | |
Total Assets | 533 | 654 | 764 | 1,769 | 1,785 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
-68 | -45 | -57 | -76 | |
-7 | -69 | -58 | -763 | |
76 | 127 | 91 | 926 | |
Net Cash Flow | 0 | 14 | -24 | 87 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 107 | 139 | 153 | 130 |
Inventory Days | 177 | 103 | 68 | 65 |
Days Payable | 48 | 99 | 132 | 88 |
Cash Conversion Cycle | 236 | 143 | 89 | 107 |
Working Capital Days | 1,210 | 1,123 | 1,086 | 855 |
ROCE % | -6% | -0% | 4% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
1d - GST demand order of INR 1.73 Cr received.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Schedule of Analyst/Institutional Investor meetings.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19 Feb
-
Intimation Of Cancellation Of Analyst/ Institutional Investor Meeting Scheduled On February 21, 2025
18 Feb - Cancellation of Analyst/Investor Meeting on Feb 21, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17 Feb - Of Schedule of Analyst / Institutional Investor meeting to be held on February 21, 2025 at 09:30 AM (IST)
Concalls
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Mar 2024Transcript PPT
Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.